Page 550 - fbkCardioDiabetes_2017

526 Cardio Diabetes Medicine 2017

the development of diabetes, MSCs have been re- strategy for the treatment of T2DM.
ported to promote islet survival against hypoxia and A total of 96 registered phase I/II clinical studies
oxidative stress. Autophagy by MSCs is one of ideal
among T2DM patients can be found with the clinical
No Stem cell Randomized Mean dose of Mode of Follow-up Assessment Assessment Publication
type placebo injected injection period of beta-cell of insulin
control study cells/kg function sensitivity
1. MNCs – – Intrapancreatic 12 month Fasting C-peptide Estrada et al. [69]
2. BM-MNCs – 3.1 × 10 6 Intra- 6 months Fasting HOMA-IR Bhansali et al. [70]
pancreatic C-peptide,
glucagon
stimulated
c-peptide,
HOMA-β
3. BM-MNCs Yes 3.2 × 10 8 Intra- 12 months Fasting HOMA-IR Bhansali et al. [71]
pancreatic C-peptide,
glucagon
stimulated
c-peptide,
HOMA-β
4. UC-MSCs – 1 × 10 6 IV + 12 months Fasting C-peptide HOMA-IR Liu et al. [72]
intrapancreatic and HOMA-β
on day 5
4. BM-MNCs Yes 2.8 × 10 9 Intra- 33 months Mixed meal Hu et al. [73]
pancreatic tolerance test
6. MNCs – (5–7) × 10 8 IV or 6 months Fasting HOMA-IR Sood et al. [75]
pancreatic C-peptide,
arterial glucagon
infusion stimulated
c-peptide,
HOMA-β
7. PD-MSCs – 1.35 × 10 6 IV 6 months Fasting C-peptide Fasting insulin Jiang et al. [77]
8. MSCs – 1.8 × 10 6 IV 6 months Fasting C-peptide Kong et al. [78]
9. BM-MSCs – (0.3–2.0) × IV 24 months Fasting C-peptide Fasting insulin Skyler et al. [83]
10 6
10. BM-MNCs Yes 3.8 × 109 Pancreatic 12 months Fasting C-peptide HOMA-IR Wu et al. [85]
arterial and OGTT
infusion
11. BM-MNCs – 3.76 × 108 Pancreatic 720 days Mixed meal Wang et al. [86]
arterial tolerance test
infusion
12. CB-SC – – IV 12 months Fasting C-peptide HOMA-IR Zhao et al. [87]
and HOMA-β
13. BM-MSCs Yes MSCs: 1 Intra- 12 months Fasting HOMA-IR, Bhansali et al. [88]
and MNCs x 106/kg; pancreatic C-peptide, HOMA-S
MNCs:109in glucagon and insulin
total stimulated sensitivity
c-peptide, index during
HOMA- β, hyperglycemic
hyperglycemic clamp
clamp
Table 1: Summary of MSC-based therapies for type 2 diabetes
MSCs mesenchymal stem cells, MNCs mononuclear stem cells, UC umbilical cord, PD placenta-derived, CB-SC cord blood-derived
multipotent stem cells, IV intravenous, HOMA-β homeostatic model assessment of beta cell function, HOMA-IR homeostasis model
assessment of insulin resistance

GCDC 2017